Unknown

Dataset Information

0

Inhibition of the Yersinia pestis Methylerythritol Phosphate Pathway of Isoprenoid Biosynthesis by ?-Phenyl-Substituted Reverse Fosmidomycin Analogues.


ABSTRACT: Fosmidomycin inhibits IspC (1-deoxy-d-xylulose 5-phosphate reductoisomerase), the first committed enzyme in the methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis. The MEP pathway of isoprenoid biosynthesis is essential to the causative agent of the plague, Yersinia pestis, and is entirely distinct from the corresponding mammalian pathway. To further drug development, we established structure-activity relationships of fosmidomycin analogues by assessing a suite of 17 ?-phenyl-substituted reverse derivatives of fosmidomycin against Y. pestis IspC. Several of these compounds showed increased potency over fosmidomycin with IC50 values in the nanomolar range. Additionally, we performed antimicrobial susceptibility testing with Y. pestis A1122 (YpA1122). The bacteria were susceptible to several compounds with minimal inhibitory concentration (MIC) values ranging from 128 to 512 ?g/mL; a correlation between the IC50 and MIC values was observed.

SUBMITTER: Ball HS 

PROVIDER: S-EPMC7081406 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of the <i>Yersinia pestis</i> Methylerythritol Phosphate Pathway of Isoprenoid Biosynthesis by α-Phenyl-Substituted Reverse Fosmidomycin Analogues.

Ball Haley S HS   Girma Misgina M   Zainab Mosufa M   Riley Honoria H   Behrendt Christoph T CT   Lienau Claudia C   Konzuch Sarah S   Avelar Leandro A A LAA   Lungerich Beate B   Soojhawon Iswarduth I   Noble Schroeder M SM   Kurz Thomas T   Couch Robin D RD  

ACS omega 20200304 10


Fosmidomycin inhibits IspC (1-deoxy-d-xylulose 5-phosphate reductoisomerase), the first committed enzyme in the methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis. The MEP pathway of isoprenoid biosynthesis is essential to the causative agent of the plague, <i>Yersinia pestis</i>, and is entirely distinct from the corresponding mammalian pathway. To further drug development, we established structure-activity relationships of fosmidomycin analogues by assessing a suite of 17 α-ph  ...[more]

Similar Datasets

| S-EPMC3205992 | biostudies-literature
| S-EPMC409939 | biostudies-literature
| S-EPMC3320496 | biostudies-literature
| S-EPMC7696990 | biostudies-literature
| S-EPMC2922546 | biostudies-literature
| S-EPMC4184463 | biostudies-literature
| S-EPMC3281858 | biostudies-literature
| S-EPMC6300130 | biostudies-literature
| S-EPMC3487848 | biostudies-literature
| S-EPMC3135366 | biostudies-literature